Organogenesis/$ORGO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Organogenesis
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Ticker
$ORGO
Sector
Primary listing
Employees
869
Headquarters
Website
Organogenesis Metrics
BasicAdvanced
$625M
-
-$0.12
1.77
-
Price and volume
Market cap
$625M
Beta
1.77
52-week high
$6.71
52-week low
$2.61
Average daily volume
801K
Financial strength
Current ratio
3.952
Quick ratio
2.938
Long term debt to equity
8.595
Total debt to equity
11.3
Interest coverage (TTM)
-35.48%
Profitability
EBITDA (TTM)
3.166
Gross margin (TTM)
74.58%
Net profit margin (TTM)
-1.92%
Operating margin (TTM)
-3.39%
Effective tax rate (TTM)
61.79%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-2.01%
Return on equity (TTM)
-2.64%
Valuation
Price to revenue (TTM)
1.479
Price to book
2.68
Price to tangible book (TTM)
3.23
Price to free cash flow (TTM)
-13.699
Free cash flow yield (TTM)
-7.30%
Free cash flow per share (TTM)
-0.36
Growth
Revenue change (TTM)
-4.21%
Earnings per share change (TTM)
-1.33%
3-year revenue growth (CAGR)
-2.27%
3-year earnings per share growth (CAGR)
-38.45%
What the Analysts think about Organogenesis
Analyst ratings (Buy, Hold, Sell) for Organogenesis stock.
Bulls say / Bears say
Surgical & Sports Medicine revenue grew 16% year-over-year to $8.1 million in Q2 2025, reflecting strong diversification beyond the main wound care business.
Organogenesis ended Q2 2025 with $73.7 million in cash and no debt, giving it solid financial flexibility to invest in research and development or strategic opportunities.
The company welcomed CMS's July 15, 2025 proposal to implement a per-square-centimeter payment model for skin substitutes, which could bring more consistent reimbursement and broader access for its PMA-approved products.
Net product revenue declined 23% year-over-year to $100.8 million in Q2 2025, driven by a 25% drop in the Advanced Wound Care segment, signaling ongoing weakness in the company’s core business.
Adjusted EBITDA went from a $15.6 million profit in the prior year to a $3.6 million loss in Q2 2025, highlighting significant pressure on margins and operational cost challenges.
Full-year 2025 revenue guidance of $480–510 million is below the consensus estimate of $531.1 million, indicating limited growth expectations and possible downside risk for investors.
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Organogenesis Financial Performance
Revenues and expenses
Organogenesis Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Organogenesis stock?
Organogenesis (ORGO) has a market cap of $625M as of September 15, 2025.
What is the P/E ratio for Organogenesis stock?
The price to earnings (P/E) ratio for Organogenesis (ORGO) stock is 0 as of September 15, 2025.
Does Organogenesis stock pay dividends?
No, Organogenesis (ORGO) stock does not pay dividends to its shareholders as of September 15, 2025.
When is the next Organogenesis dividend payment date?
Organogenesis (ORGO) stock does not pay dividends to its shareholders.
What is the beta indicator for Organogenesis?
Organogenesis (ORGO) has a beta rating of 1.77. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.